First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL

YF2 - Columbia University Irving Medical Center

Istodax (romidepsin) - Astellas, BMS

Jakafi (ruxolitinib) - Incyte

Beleodaq (belinostat) - Aurobindo, Assertio

Farydak (panobinostat) - Secura Bio

https://ash.confex.com/ash/2023/webprogram/Paper186639.html

Manuel Pazos II, MS, BS1; Brian Estrella, PhD1; Ted B. Piorczynski, PhD2; Seda S. Tolu, MD3; Wenxuan Huang1; Yun Kyoung Ryu, MD, PhD1; Jennifer E Amengual, MD4

Nov 3, 2023